Co-Authors
This is a "connection" page, showing publications co-authored by MAKSIM MAMONKIN and NORIHIRO WATANABE.
Connection Strength
2.535
-
Feasibility and preclinical efficacy of CD7-unedited CD7 CAR T?cells for T?cell malignancies. Mol Ther. 2023 01 04; 31(1):24-34.
Score: 0.895
-
Off-the-Shelf Chimeric Antigen Receptor T Cells: How Do We Get There? Cancer J. 2021 Mar-Apr 01; 27(2):176-181.
Score: 0.805
-
Human platelet lysate enhances in vivo activity of CAR-Vd2 T cells by reducing cellular senescence and apoptosis. Cytotherapy. 2024 Mar 12.
Score: 0.248
-
Engineering T cells to suppress acute GVHD and?leukemia relapse after allogeneic hematopoietic stem cell transplantation. Blood. 2023 03 09; 141(10):1194-1208.
Score: 0.231
-
Engineered off-the-shelf therapeutic T cells resist host immune rejection. Nat Biotechnol. 2021 01; 39(1):56-63.
Score: 0.193
-
Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia. Blood. 2024 Jan 19.
Score: 0.061
-
Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy. Cytotherapy. 2022 03; 24(3):282-290.
Score: 0.053
-
Modulating TNFa activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer. 2020 09; 8(2).
Score: 0.049